Stay updated on IMP321 for Advanced Solid Tumors Clinical Trial.
Sign up to get notified when there's something new on the IMP321 for Advanced Solid Tumors Clinical Trial. page.

Latest updates to the IMP321 for Advanced Solid Tumors Clinical Trial. page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference5%
- Check39 days agoChange DetectedThe page has updated the date related to the feasibility and safety study of IMP321 (eftilagimod Alpha) for advanced stage solid tumors, changing it from November 7, 2024, to February 13, 2025.SummaryDifference1%
- Check46 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference6%
- Check53 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.3%
- Check68 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.3%
- Check75 days agoChange DetectedThe website has updated the 'type of intervention' feature from version v2.13.3 to v2.14.0, indicating a significant change in this functionality.SummaryDifference1.0%
Stay in the know with updates to IMP321 for Advanced Solid Tumors Clinical Trial.
Enter your email address, and we'll notify you when there's something new on the IMP321 for Advanced Solid Tumors Clinical Trial. page.